Northland Securities analyst Carl Byrnes maintained a Buy rating on MiMedx Group (MDXG – Research Report) today and set a price target of $12.00. The company’s shares closed yesterday at $9.23.
Byrnes covers the Healthcare sector, focusing on stocks such as MiMedx Group, Durect, and Heron Therapeutics. According to TipRanks, Byrnes has an average return of -6.8% and a 36.27% success rate on recommended stocks.
MiMedx Group has an analyst consensus of Strong Buy, with a price target consensus of $12.75.
The company has a one-year high of $9.49 and a one-year low of $5.47. Currently, MiMedx Group has an average volume of 744.6K.
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
MiMedx Group (MDXG) Company Description:
MiMedx Group, Inc. is an advanced wound care and an emerging therapeutic biologics company. It engages in developing and distributing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. The company processes the human placental tissue utilizing its proprietary PURION process methodology, among other processes, to produce allografts by employing aseptic processing techniques in addition to terminal sterilization. MiMedx Group was founded on July 30, 1985 and is headquartered in Marietta, GA.
